Yazar "Gulmez, Nurhayat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Effect of Kefir on Increased Apoptosis in Liver and Kidney in Cisplatin Toxicity
    (Soc Chilena Anatomia, 2022) Sah, Huseyin; Gulmez, Nurhayat; Soyler, Gizem; Sayiner, Serkan; Sehirli, Ahmet Ozer; Kukner, Aysel
    Cisplatin is a chemotherapeutic agent inducing liver and kidney damage. In this study, we intended to investigate the impact of kefir beverage, an essential probiotic and functional food, on liver and kidney damage induced by cisplatin. Wistar albino rats were divided into four groups: Control, Cisplatin (single dose of 7 mg/kg, intraperitoneal), Kefir (2 ml/d, 7 d, oral gavage), and Cisplatin+Kefir (CK). At the end of day 7, animals were euthanized. Blood, kidney, and liver tissue samples were collected. For both tissues, biochemically ALT, AST, Urea, Creatine; histomorphologically, hematoxylin-eosin, Masson's Trichrome, and immunohistochemical staining of caspase-3, a marker of apoptosis, were performed. Serum urea and creatinine levels of the Cisplatin group were significantly higher than the Control group (p<0.05). In the CK group, kefir consumption decreased urea and creatinin levels approached to Control and Kefir groups. Cisplatin resulted in higher ALT and AST activities, indicating hepatocellular damage, compared to the Control group (p<0.05). Kefir consumption decreased ALT activities approached to both the Control and Kefir group. Histomorphological observations were in agreement biochemical results. In liver and kidney tissues, structural damage was observed with an increase in collagen fibers in the Cisplatin group, and Caspase-3 activity was immunohistochemically higher than in the other groups. In the CK group, collagen fiber increase, structural damage, and Caspase-3 activities were less than in the Cisplatin group. Kefir consumption alleviated liver and kidney damage. However, more research is required to understand such effect of kefir better.
  • [ X ]
    Öğe
    Protective Effects of Alpha-Lipoic Acid against 5-Fluorouracil-Induced Gastrointestinal Mucositis in Rats
    (Mdpi, 2022) Ceylanli, Deniz; Sehirli, Ahmet Ozer; Gencosman, Sevgi; Terali, Kerem; Sah, Huseyin; Gulmez, Nurhayat; Sayiner, Serkan
    Alpha-lipoic acid (ALA) is extensively utilized in multivitamin formulas and anti-aging products. The purpose of this study was to investigate the potential protective benefits of ALA on 5-fluorouracil (5-FU)-induced gastrointestinal mucositis in Wistar albino rats. Tissues from the stomach, small intestine, and large intestine were excised, and blood sera were obtained to identify biochemical indices such as TNF-alpha, IL-1 beta, MDA, GPx, SOD, MMP-1, -2, -8, and TIMP-1. A histopathological study was also performed. The results revealed mucositis-elevated TNF-, IL-1, MDA, MMP-1, -2, -8, and TIMP-1 levels in both tissues and sera, and these values dropped dramatically following ALA treatment. Reduced SOD and GPx activities in mucositis groups were reversed in ALA-treated groups. The damage produced by mucositis in the stomach and small intestine regressed in the ALA-treated group, according to histopathological evaluation. Consequently, the implementation of ALA supplementation in 5-FU therapy may act as a protective intervention for cancer patients with gastrointestinal mucositis. In light of the findings, ALA, a food-derived antioxidant with pleiotropic properties, may be an effective treatment for 5-FU-induced gastrointestinal mucositus, and prevent oxidative stress, inflammation, and tissue damage in cancer patients receiving 5-FU therapy.
  • [ X ]
    Öğe
    The evaluation of the protective effect of ambroxol against acetaminophen-induced hepatorenal toxicity in rats
    (Marmara Univ, 2024) Sayiner, Serkan; Gencosman, Sevgi; Sah, Huseyin; Gulmez, Nurhayat; Sehirli, Ahmet Ozer
    Acetaminophen (APAP), widely used as an analgesic-antipyretic drug, can cause liver and kidney damage at high doses. This study explored the protective effects of a mucolytic agent and an antioxidant Ambroxol (AMB), against APAP-induced toxicity in rats. The experiment included four groups of Wistar albino rats each having 6 animals in both sexes: a control group, an AMB-only group (50 mg/kg orally), an APAP-only group (1000 mg/kg intraperitoneally), and a combination APAP+AMB group. Twenty-four hours following the administration of APAP administration, rats were sacrificed. Measurements of blood levels of liver enzymes (AST, ALT, ALP, LDH), kidney function markers (Urea, Creatinine), and antioxidant enzymes (SOD, GPx) were performed. GPx and SOD activities were also assessed in hepatic and renal tissue samples. Histological examination of hepatic and renal tissues was conducted using Haematoxylin and Eosin staining. Results showed that APAP significantly increased liver enzymes, BUN, and Creatinine levels, indicating hepatorenal damage. This was accompanied by a decrease in plasma GPx and SOD activities. However, AMB treatment significantly mitigated these changes. It improved enzyme activities and increased hepatic GPx. Histologically, the APAP group showed liver cell damage, necrosis, haemorrhage, and inflammation, which were notably reduced in the AMB-treated group. This study suggests that Ambroxol effectively counters APAPinduced hepatorenal damage by restoring antioxidant enzyme levels and normalizing functional enzyme activities, highlighting its potential as a protective agent.